Why the study?
To evaluate the cost-effectiveness of the HeartMate3 support system versus optimal drug therapy in patients with severe chronic heart failure and assess its budget impact in the Russian Federation.
Is the HeartMate3 system cost-effective compared to optimal drug therapy in patients with severe chronic heart failure and reduced LVEF?
Is the HeartMate3 system cost-effective compared to optimal drug therapy in patients with severe chronic heart failure and reduced LVEF?
HeartMate3 implantation in severe heart failure patients becomes increasingly cost-effective over longer time horizons with a modest impact on the healthcare budget in the Russian Federation.
Answers are grounded in this paper and cite their sources.
May not support routine HeartMate3 adoption at standard horizons; leaves open longer-term cost-effectiveness in Russian severe HF.
Objective. Cost-effectiveness analysis of HeartMate3 support system and optimal drug therapy in patients with severe chronic heart failure (CHF); to analyze potential impact of HeartMate3 implantation on healthcare budget in the Russian Federation. Material and methods. The target population included patients with CHF NYHA class III—IV and reduced left ventricular ejection fraction. Cost-effectiveness analysis of HeartMate3 device and ODT in target population was carried out in the Markov model with a modeling time horizon of 5, 6, 8, 12 and 15 years. We estimated the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year for HeartMate3 and ODT. Budget impact analysis implied the costs of current and expected practice of treating CHF in target population from the healthcare system point of view. The current practice was ODT only, the expected practice — HeartMate3 (minimum, optimal and maximum scenarios with annual number of implantations from 70 to 700). Results. The (ICER) per quality-adjusted life year for HeartMate3 compared to ODT amounted to 6.2 million rubles in 5-year modeling horizon and 3.6 million rubles in 15-year horizon. HeartMate3 will lead increase healthcare costs over 5 years by 14 (+1.48%), 24 (+2.57%) or 40.6 billion rubles (+4.32%) for the minimum, optimal and maximum implantation implementation scenarios, respectively. Conclusion. Cost-effectiveness of HeartMate3 increases as the simulation time horizon increases. Healthcare costs will increase only slightly even in maximum scenario of HeartMate3 implementation (700 implantations annually for 5 years).
No takes yet. Share an insight, caveat, or question.
Оmelyanovskiy et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: